Seroatlas · Human Serome Atlas

LAG3

Lymphocyte activation gene 3 protein

Also known as: CD223, LAG3_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P18627
Gene
LAG3
Ensembl
ENSG00000089692
Chromosome
12
Canonical length
525 aa
Protein class
CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins
Secretome location
Intracellular and membrane
Quaternary structure
Homodimer

OverviewNCBI Gene

Lymphocyte-activation protein 3 belongs to Ig superfamily and contains 4 extracellular Ig-like domains. The LAG3 gene contains 8 exons. The sequence data, exon/intron organization, and chromosomal localization all indicate a close relationship of LAG3 to CD4. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

525 residues, UniProt reviewed canonical sequence.

>P18627|LAG3
     1  MWEAQFLGLL FLQPLWVAPV KPLQPGAEVP VVWAQEGAPA QLPCSPTIPL QDLSLLRRAG
    61  VTWQHQPDSG PPAAAPGHPL APGPHPAAPS SWGPRPRRYT VLSVGPGGLR SGRLPLQPRV
   121  QLDERGRQRG DFSLWLRPAR RADAGEYRAA VHLRDRALSC RLRLRLGQAS MTASPPGSLR
   181  ASDWVILNCS FSRPDRPASV HWFRNRGQGR VPVRESPHHH LAESFLFLPQ VSPMDSGPWG
   241  CILTYRDGFN VSIMYNLTVL GLEPPTPLTV YAGAGSRVGL PCRLPAGVGT RSFLTAKWTP
   301  PGGGPDLLVT GDNGDFTLRL EDVSQAQAGT YTCHIHLQEQ QLNATVTLAI ITVTPKSFGS
   361  PGSLGKLLCE VTPVSGQERF VWSSLDTPSQ RSFSGPWLEA QEAQLLSQPW QCQLYQGERL
   421  LGAAVYFTEL SSPGAQRSGR APGALPAGHL LLFLILGVLS LLLLVTGAFG FHLWRRQWRP
   481  RRFSALEQGI HPPQAQSKIE ELEQEPEPEP EPEPEPEPEP EPEQL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against LAG3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
1
Mean surface accessibility (rSASA)
0.41
Highest tissue expression
22 nTPM

Expression across tissuesHPA

Tissue

  • spleen: 22 nTPM
  • ovary: 18 nTPM
  • lymph node: 15 nTPM
  • choroid plexus: 13 nTPM
  • tonsil: 10 nTPM
  • endometrium: 7.2 nTPM

Single-cell type

  • peritubular myoid cells: 69 nCPM
  • t-cells: 55 nCPM
  • leydig cells: 39 nCPM
  • ovarian stromal cells: 28 nCPM
  • hofbauer cells: 28 nCPM
  • breast secretory cells: 25 nCPM

Immune cell

  • gdT-cell: 13 nTPM
  • memory CD8 T-cell: 11 nTPM
  • MAIT T-cell: 10 nTPM
  • naive CD8 T-cell: 4.2 nTPM
  • memory CD4 T-cell: 2.4 nTPM
  • T-reg: 2 nTPM

Brain region

  • choroid plexus: 8.5 nTPM
  • cerebral cortex: 1.1 nTPM
  • spinal cord: 1 nTPM
  • medulla oblongata: 0.9 nTPM
  • pons: 0.6 nTPM
  • white matter: 0.6 nTPM

ReferencesPubMed · IEDB

Publications for LAG3 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.

Reference: AutoantibodyPubMed

1 publication

Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.5
gnomAD pLI
0.28
gnomAD missense Z
0.51
DepMap mean gene effect
-0.04
DepMap dependency class
none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of LAG3 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads LAG3 as an antibody target. Whether an autoantibody or antibody against LAG3 could matter depends on whether native LAG3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

LAG3 is annotated at the cell surface, where native LAG3 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label LAG3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/LAG3. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...